Macquarie Group’s FibroBiologics FBLG Stock Holding History

Macquarie Group’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-54	Closed	-$12	–	2165
2024 Q1	$12	Buy	+54	New	+$13K	﹤0.01%	1719

Other funds holding FBLG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return

OAS

Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return

RCM

Requisite Capital Management Dallas, Texas $537M AUM 12.29% 1-Year Est. Return

AIFAIM

American Institute for Advanced Investment Management Scottsdale, Arizona $154M AUM 21.65% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Macquarie Group's FBLG Position: Q2 2024 in Review

Macquarie Group sold out of FibroBiologics (FBLG) in Q2 2024, closing a stake of 54 shares — an estimated $12 sold.

Macquarie Group first reported a position in FBLG in Q1 2024 and held it in 1 quarter. The position peaked at $12 in Q1 2024. 50 funds tracked by Wall St. Rank hold FBLG as of Q2 2024.

Macquarie Group reported no remaining FibroBiologics position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 54 FibroBiologics shares in Q2 2024, an estimated $12.
Macquarie Group first reported a position in FibroBiologics in Q1 2024 and held it in 1 quarter.
Macquarie Group's FibroBiologics position peaked at $12 in Q1 2024.
50 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.